Heavy menstrual bleeding assessment

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Heavy menstrual bleeding is a symptom defined by impact rather than a compulsory pictorial score or 80 mL threshold. Ask how bleeding affects work, sleep, exercise, relationships, religious practice, finances and ability to leave home. Translate broad descriptions into observable events: flooding through clothes or bedding, changing protection more often than every one to two hours, double protection, night changes and clots. These features estimate burden but do not identify cause. Establish when the change began and whether every cycle or only occasional cycles are affected.

Build the menstrual pattern. Record the last normal menstrual period, usual interval and variability, days of bleeding, pain, bleeding between periods or after sex, and perimenopausal or hormonal-treatment context. Pregnancy testing is based on pregnancy potential and timing, not age assumptions. Cyclical pain and a bulky tender uterus support adenomyosis; pressure, urinary frequency or an irregular enlarged uterus support fibroids; intermenstrual bleeding raises a cavity or endometrial lesion. No pattern alone excludes malignancy.

Review systemic and iatrogenic contributors. Ask about easy bruising, nosebleeds, prolonged bleeding after dental work or birth, postpartum haemorrhage and affected relatives, especially when heavy periods started at menarche. Record anticoagulants, antiplatelets, copper intrauterine contraception, hormonal methods, tamoxifen and medicines affecting ovulation. Consider endocrine or ovulatory dysfunction through infrequent cycles, androgen features, thyroid symptoms, major weight change, hyperprolactinaemia clues and perimenopause rather than ordering an indiscriminate hormone panel.

NICE recommends full blood count for all HMB while treatment is arranged. Interpret haemoglobin and indices with symptoms and prior results; normal haemoglobin does not mean the bleeding is unimportant, and iron depletion can precede anaemia. Ferritin is not required routinely by NG88 but should be used when a separate iron-deficiency question exists. Coagulation tests are selective for bleeding since menarche plus a suggestive personal or family history and may need von Willebrand and specialist assessment beyond a normal PT or APTT.

Examination depends on associated features and proposed treatment. Abdominal and pelvic examination is indicated when there is pain, pressure, a mass, intermenstrual or postcoital bleeding, treatment failure or before fitting an LNG-IUS. Obtain specific consent and a chaperone for intimate examination. Assess pallor, haemodynamic state, abdominal mass and pelvic findings. Speculum examination can identify cervical or vaginal bleeding; bimanual examination estimates uterine size and tenderness but cannot clear endometrial or adnexal disease.

NICE permits initial pharmacological management without investigation when history and examination, if needed, suggest a low risk of structural or endometrial pathology. Investigation is targeted. Outpatient hysteroscopy is the prioritised initial test when a submucosal fibroid, polyp or endometrial pathology is suspected. Pelvic ultrasound comes first for a palpable uterus, suspected pelvic mass or difficult examination. Transvaginal ultrasound is preferred when adenomyosis is suspected. MRI and saline-infusion sonography are not first-line HMB investigations.

Endometrial sampling is not a routine blind test for every heavy period. NICE recommends considering biopsy at hysteroscopy when endometrial risk is higher: persistent intermenstrual or irregular bleeding, infrequent heavy bleeding with obesity or PCOS, tamoxifen use, or unsuccessful treatment. The cavity view allows targeted assessment, and an insufficient sample requires an explicit next step. Postmenopausal bleeding uses a separate urgent cancer pathway.

Finish by agreeing priorities. For some patients contraception and bleeding suppression align; others are trying to conceive or want to preserve the uterus. Explain that an LNG-IUS can take several cycles to achieve full benefit, non-hormonal medicines work only when taken during bleeding, and large or cavity-distorting fibroids reduce success of some medical options. Treat iron deficiency, provide escalation for acute worsening and define when non-response leads to specialist care.

Key points

NICE defines heavy menstrual bleeding by adverse physical, social, emotional or material quality-of-life effects; an exact measured blood volume is not required.
Clarify cycle interval and regularity, bleeding duration, flooding, clots, night changes, products used, pain, intermenstrual or postcoital bleeding, change from baseline and impact on activity.
Ask about pregnancy possibility, contraception, fertility goals, anticoagulants, tamoxifen, PCOS or infrequent cycles, obesity, pelvic pressure, discharge and relevant personal or family bleeding history.
NICE recommends a full blood count for every patient with HMB, performed in parallel with treatment; ferritin is not a routine universal test but is appropriate when iron deficiency is clinically suspected.
Consider coagulation testing when heavy bleeding has been present since periods began and the personal or family history suggests a bleeding disorder.
Do not routinely order female hormone tests, and request thyroid function only when other symptoms or signs suggest thyroid disease.
If history suggests low risk of fibroid, cavity abnormality, adenomyosis or endometrial disease, NICE allows pharmacological treatment without investigation; examine before an LNG-IUS is fitted.
Choose outpatient hysteroscopy first when submucosal fibroid, polyp or endometrial pathology is suspected, particularly with persistent intermenstrual bleeding or relevant risk factors.
Choose pelvic ultrasound first when the uterus is palpable abdominally, a pelvic mass is suspected or examination is inconclusive or difficult; prefer transvaginal ultrasound for suspected adenomyosis.
Agree whether the priority is bleeding reduction, pain control, contraception, fertility preservation or definitive treatment, then set a review point rather than escalating without reassessment.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Structural uterine disease

Polyps, adenomyosis, fibroids, hyperplasia and malignancy alter cavity surface, myometrial contraction or tissue fragility and can increase or irregularise bleeding.

Ovulatory and endometrial dysfunction

Irregular ovulation changes progesterone exposure and endometrial stability, while local haemostatic dysfunction can cause heavy regular bleeding despite normal anatomy.

Haemostatic and iatrogenic factors

Inherited bleeding disorders, anticoagulants, copper intrauterine contraception, tamoxifen and some hormonal regimens can increase or destabilise uterine bleeding.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Expanded bleeding surface
Cavity-distorting fibroids and polyps increase or disrupt endometrial surface and vascular architecture, contributing to prolonged or unpredictable loss.
2
Impaired myometrial compression
Adenomyosis and intramural fibroids can reduce coordinated uterine contraction around endometrial vessels and coexist with prostaglandin-mediated pain.
3
Unopposed proliferation
Infrequent ovulation can expose endometrium to oestrogen without regular progesterone organisation and shedding, producing irregular heavy episodes and hyperplasia risk.
4
Iron depletion cycle
Repeated loss consumes iron stores, causing fatigue and reduced function before or alongside anaemia, which may make subsequent bleeding less tolerable.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Quality-of-life burden

Flooding, night waking, activity restriction, missed work, anxiety about leakage or unaffordable protection makes bleeding clinically heavy even without anaemia.

Anaemia phenotype

Fatigue, exertional breathlessness, palpitations, pallor, headache or pica suggests iron deficiency or anaemia and supports prompt blood testing and replacement.

Cavity pathology pattern

Persistent intermenstrual bleeding, irregular bleeding or risk factors for endometrial disease makes hysteroscopy more appropriate than empirical treatment alone.

Fibroid pattern

Pelvic pressure, urinary frequency, an abdominally palpable uterus or an irregular enlarged uterus suggests leiomyoma and leads to pelvic imaging.

Adenomyosis pattern

Progressively painful heavy periods with a bulky tender uterus favours adenomyosis and makes transvaginal ultrasound the preferred imaging route.

Bleeding disorder pattern

HMB from menarche with bruising, epistaxis, procedural bleeding or affected relatives suggests inherited haemostatic disease despite otherwise normal pelvic findings.

Red flags requiring action

Bleeding with a positive or uncertain pregnancy test, unilateral pain, shoulder-tip pain or collapse may be ectopic pregnancy or pregnancy loss and needs urgent location assessment.
Persistent intermenstrual bleeding, postcoital bleeding, postmenopausal bleeding, a suspicious cervix or endometrial cancer risk shifts assessment towards urgent direct investigation.
A palpable abdominal or pelvic mass, marked distension, pressure symptoms or new urinary or bowel dysfunction requires structural imaging and specialist review.
Heavy bleeding since menarche plus personal or family bleeding history suggests an inherited coagulation disorder and warrants directed testing with haematology input.
Severe symptomatic anaemia, cardiovascular compromise or rapidly falling haemoglobin requires urgent stabilisation; a laboratory number cannot replace physiological assessment.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Pregnancy testFirst step
Why
Exclude pregnancy-related bleeding before assigning a non-pregnant uterine pathway or prescribing relevant treatment.
Interpretation and limitations
Seek consent and interpret against timing. A positive result requires location and viability assessment when pain or bleeding is present; an early negative may need repetition.
02
Full blood count
Why
Measure anaemia and indices in every patient with HMB while treatment proceeds.
Interpretation and limitations
NICE makes this universal. Severity and urgency depend on symptoms, haemodynamics and trajectory as well as haemoglobin; microcytosis supports iron depletion but is not required.
03
Selective coagulation assessment
Why
Investigate inherited bleeding disorder when HMB began at menarche and history is suggestive.
Interpretation and limitations
A normal routine clotting screen does not exclude von Willebrand disease or platelet dysfunction; discuss appropriate timing and specialist assays with haematology.
04
Outpatient hysteroscopy
Why
Directly inspect the cavity when a polyp, submucosal fibroid or endometrial lesion is suspected.
Interpretation and limitations
This is NICE’s first investigation for the relevant pattern. Consider biopsy during hysteroscopy for high-risk features; do not substitute blind biopsy.
05
Pelvic ultrasound
Why
Assess uterine size, fibroids, adenomyosis and adnexa when examination or symptoms indicate structural disease.
Interpretation and limitations
Use transvaginal scanning for greater detail and suspected adenomyosis when acceptable. Ultrasound can miss focal cavity pathology and does not provide histology.
06
Selective thyroid, ferritin or endocrine tests
Why
Answer a separate clinical hypothesis such as thyroid disease, iron deficiency or ovulatory dysfunction.
Interpretation and limitations
NG88 advises against routine thyroid and female hormone testing. Selective results should be interpreted with symptoms and cycle pattern, not used as a screening panel.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Pregnancy-related bleeding

Pregnancy loss and ectopic pregnancy can be mistaken for an unusually heavy or late period, particularly when cycle timing is unreliable.

Cervical or vaginal bleeding

Cervicitis, ectropion, polyps, trauma and malignancy can appear menstrual unless timing, speculum findings and source are established.

Urinary or rectal blood

Haematuria and rectal bleeding may be noticed on menstrual products; focused history and examination localise the anatomical source.

Systemic bleeding disorder

Von Willebrand disease, platelet dysfunction and acquired coagulopathy often cause bleeding at other sites and disproportionate loss from menarche.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01First assessmentMeasure danger, burden and pregnancy contextFirst stepA patient describes periods as heavy, prolonged or increasingly disruptive.

1Check physiology and acute blood loss, establish pregnancy possibility, and elicit cycle pattern, flooding, associated bleeding, pain, pressure and quality-of-life impact.
2Review medicines, contraception, fertility priorities, endometrial risk and bleeding-disorder history, then examine when symptoms or the proposed treatment requires it.
3Arrange full blood count in parallel with initial safe treatment and give clear urgent return advice for collapse, severe pain or uncontrolled flooding.

02Low structural riskTreat before imaging when the history supports itThere is no intermenstrual bleeding, mass, marked pain, endometrial risk or failed prior treatment.

1PreferredDiscuss an LNG-IUS as NICE’s preferred option when no pathology or small non-distorting fibroids are expected, incorporating contraception and fertility wishes.
2If unsuitable or declined, offer tranexamic acid, an NSAID, combined hormonal contraception or cyclical oral progestogen according to contraindications and goals.
3Set a defined review after adequate use and investigate if response is poor, the pattern changes or new structural or cancer features appear.

03Cavity or endometrial riskUse direct visual assessmentPersistent intermenstrual or irregular bleeding, tamoxifen, PCOS with infrequent heavy bleeding, obesity-related risk or treatment failure is present.

1Offer outpatient hysteroscopy, explain awake and anaesthetic alternatives and whether a see-and-treat procedure may be possible.
2Consider endometrial biopsy during hysteroscopy according to risk and obtain targeted tissue from abnormal areas where feasible.
3EscalationTrack histology and cavity findings to treatment, repeating or escalating an incomplete examination rather than recording normality.

04Mass or adenomyosisMap myometrium and pelvisThe uterus is palpable, examination is difficult, a mass is suspected or dysmenorrhoea and tenderness suggest adenomyosis.

1Arrange pelvic ultrasound, preferring transvaginal imaging for suspected adenomyosis and explaining transabdominal limitations if internal scanning is declined.
2Record fibroid size, location, number, cavity distortion and adnexal findings and relate these to symptoms and fertility plans.
3Refer fibroids of 3 cm or more, complex masses, severe symptoms or failed medical treatment for specialist procedural discussion.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Iron deficiency and anaemia

Progressive iron loss causes fatigue, cognitive difficulty, pica, breathlessness, tachycardia and, when severe, cardiovascular stress or transfusion need.

Functional and psychological harm

Unpredictable flooding can restrict work, education, exercise, intimacy and travel and create persistent anxiety about leakage or access to products.

Delayed serious diagnosis

Treating all bleeding empirically can postpone recognition of endometrial disease, cervical cancer, a bleeding disorder or pregnancy complication.

Treatment-related morbidity

Hormonal thrombosis risk, NSAID toxicity, device complications and procedural effects on fertility require individual selection and follow-up.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Review bleeding days, flooding, night changes, pain, activity and patient-defined goals rather than using haemoglobin as the only outcome.
Repeat full blood count according to baseline anaemia, ongoing loss and treatment; assess ferritin or response when iron deficiency is being treated.
Track every hysteroscopy, biopsy and ultrasound to a named reviewer, including incomplete cavity views and insufficient histology.
Reassess pregnancy possibility, intermenstrual or postcoital bleeding, mass symptoms and cancer risk whenever the pattern changes or treatment fails.
Escalate acute haemodynamic symptoms, severe pain, rapidly increasing bleeding or inability to function despite the agreed outpatient plan.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Impact defines heaviness

A patient does not need to prove a volume threshold; practical loss, distress and restriction are sufficient to justify assessment and treatment.

Normal haemoglobin is not normal bleeding

Physiological adaptation and iron stores can temporarily preserve haemoglobin while quality of life deteriorates and depletion progresses.

History selects the camera

Cavity-pattern symptoms favour hysteroscopy, whereas uterine enlargement or adenomyosis features favour ultrasound; ordering both reflexively can delay the useful test.

Coagulation screens have blind spots

Von Willebrand disease and platelet disorders may exist despite routine PT and APTT, making personal and family bleeding history essential.

Fertility changes success

A treatment that suppresses bleeding through contraception may be unsuitable when conception is desired, while uterine-preserving procedures can still affect pregnancy outcomes.

11Common pitfallsFrequent interpretation and management errors.

01
Requiring an exact menstrual blood volume before accepting that bleeding is clinically heavy.
02
Ordering ferritin, thyroid and female hormone tests universally while omitting the NICE-required full blood count.
03
Using pelvic ultrasound instead of hysteroscopy when persistent intermenstrual bleeding suggests cavity pathology.
04
Performing blind endometrial biopsy in the HMB pathway rather than sampling during hysteroscopy when indicated.
05
Assuming a normal bimanual examination excludes adenomyosis, fibroids or endometrial disease.
06
Starting treatment without agreeing fertility, contraceptive and quality-of-life priorities or a review point.